| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2025 ( Subtotal = $1,059,334 ) |
| 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI187674 | C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis | 000 | 1 | NIH | 11/13/2024 | $265,650 |
| 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI182977 | Tissue specific immunity to fungal infections | 000 | 1 | NIH | 11/22/2024 | $857,215 |
| 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 06 | 5 | CMS | 10/29/2024 | $0 |
| 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 05 | 5 | CMS | 10/4/2024 | $0 |
| 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2249945 | Dental Reimbursement Program | 01 | 1 | HRSA | 12/4/2024 | $0 |
| 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI138986 | Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | 000 | 5 | NIH | 11/22/2024 | $0 |
| 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T1433114 | ANE - Nurse Practitioner Residency Program | 04 | 4 | HRSA | 11/13/2024 | -$63,531 |
| 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HD090180 | Epigenetics of Down Syndrome | 000 | 6 | NIH | 11/19/2024 | $0 |
| 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA212639 | Targeting Transcriptional Co-repressor CoREST Complex in Melanoma | 000 | 5 | NIH | 11/25/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $21,654,919 ) (Continued on the next page) |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K22CA288932 | Cancer Misinformation and Use of Complementary and Alternative Therapy (CAM) among Patients with Cancer. | 000 | 1 | NIH | 6/28/2024 | $194,400 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI177342 | Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease | 000 | 2 | NIH | 5/20/2024 | $838,280 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA283566 | Nuclear envelope and predisposition to hepatic neoplasia | 003 | 3 | NIH | 7/25/2024 | $384,860 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AA030625 | Peptide therapy for alcohol-induced CNS injury | 000 | 2 | NIH | 5/21/2024 | $210,306 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 001 | 2 | NIH | 4/22/2024 | $36,996 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 002 | 2 | NIH | 5/10/2024 | -$32,188 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 000 | 2 | NIH | 3/13/2024 | $665,916 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 02 | 5 | CMS | 5/23/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 01 | 5 | CMS | 2/15/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 03 | 5 | CMS | 6/14/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 5 | CMS | 12/15/2023 | $2,000,000 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 04 | 5 | CMS | 8/9/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 001 | 3 | NIH | 4/17/2024 | $27,724 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 3 | NIH | 1/29/2024 | $498,997 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA229979 | Experimental evolution of pancreatic cancer | 000 | 5 | NIH | 7/11/2024 | $249,000 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245123 | Elucidating the Role of SMAD4 in Colorectal Cancer | 000 | 5 | NIH | 6/7/2024 | $249,000 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 001 | 5 | NIH | 4/18/2024 | $24,899 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 000 | 5 | NIH | 3/21/2024 | $224,101 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA254274 | Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy | 002 | 5 | NIH | 5/6/2024 | $381,058 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI084385 | I.C.A.R.E. - Integrated Care for Addiction Recovery Expansion | 001 | 4 | SAMHSA | 7/2/2024 | $524,904 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | 002 | 7 | NIH | 9/4/2024 | $87,280 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | 001 | 7 | NIH | 7/2/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | 000 | 7 | NIH | 6/21/2024 | $804,774 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI121080 | CTCF in CD8 T cell homeostasis and anti-viral/tumor immunity | 001 | 8 | NIH | 7/22/2024 | $523,039 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI109025 | Critical Factors Influencing Echinocandin Resistance in Candidaglabrata | 001 | 12 | NIH | 7/2/2024 | $837,746 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79SM084539 | Hackensack Meridian Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (AIDE) | 000 | 4 | SAMHSA | 5/30/2024 | $124,990 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K00CA264409 | Optimizing adherence to lung cancer screening: Applying theory and implementation science to participant engagement | 000 | 4 | NIH | 8/21/2024 | $103,871 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 001 | 4 | NIH | 6/20/2024 | $50,679 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 001 | 2 | NIH | 5/13/2024 | $23,330 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HL154757 | DOT1L, reconstitution of plasmacytoid dendritic cells and alloimmunity | 000 | 4 | NIH | 4/18/2024 | $570,153 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 000 | 2 | NIH | 10/25/2023 | $209,973 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI112579 | Tcf1 programs CD8 T cell responses to enhance viral and cancer immunity | 000 | 9 | NIH | 4/30/2024 | $516,631 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01NS133233 | Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy. | 000 | 1 | NIH | 3/5/2024 | $442,750 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI174118 | Identifying drug-resistant Candida species using SuperSelective primer PCR | 001 | 2 | NIH | 5/9/2024 | $20,373 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI174118 | Identifying drug-resistant Candida species using SuperSelective primer PCR | 000 | 2 | NIH | 10/30/2023 | $183,368 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI161013 | Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | 000 | 4 | NIH | 6/7/2024 | $1,273,323 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 000 | 5 | NIH | 3/20/2024 | $747,157 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 001 | 5 | NIH | 7/17/2024 | $0 |
| 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA263662 | Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge and Uptake in High-Risk Populations | 000 | 4 | NIH | 8/12/2024 | $651,814 |
|